BriaCell Therapeutics Corp. (BCTX)
| Market Cap | 26.81M +14.6% |
| Revenue (ttm) | n/a |
| Net Income | -34.90M |
| EPS | -6.99 |
| Shares Out | 8.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 130,852 |
| Open | 3.350 |
| Previous Close | 3.310 |
| Day's Range | 2.950 - 3.350 |
| 52-Week Range | 2.600 - 13.430 |
| Beta | 1.51 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About BCTX
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore Co... [Read more]
Financial Performance
Financial StatementsNews
BriaCell Therapeutics Annual report: Q4 2026
BriaCell Therapeutics has published its Q4 2026 annual report on October 28, 2026.
BriaCell Therapeutics Report: Q4 2026
BriaCell Therapeutics published a report on October 28, 2026 containing material business information for investors and shareholders.
BriaCell Therapeutics MD&A: Q4 2026
BriaCell Therapeutics filed a regulatory document on October 28, 2026 disclosing important business information.
BriaCell presents clinical biomarker findings from MBC patients at ESMO
BriaCell (BCTX) announced the presentation of clinical biomarker findings from a prospective pooled analysis of patients with metastatic breast cancer, or MBC, treated with immune based therapies incl...
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...
BriaCell announces DSMB recommendation to continue Bria-ABC study
BriaCell (BCTX) announced that the independent Data Safety Monitoring Board, or DSMB, has issued its seventh consecutive recommendation following review of clinical data from BriaCell’s Phase 3 Bria-A...
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnol...
BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnol...
BriaCell advances melanoma immunotherapy vaccine candidate Bria-MEL+
BriaCell (BCTX) announced that Bria-MEL+, its personalized whole cell melanoma immunotherapy vaccine candidate, has achieved a genetic engineering milestone, advancing the program toward clinical deve...
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
Cell-based immunotherapy program is designed to harness patients' own immune systems Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific trea...
BriaCell gets FDA clearance for Bria-PROS+ study in prostate cancer
BriaCell (BCTX) Therapeutics announced that the FDA has completed its review of the Investigational New Drug application for Bria-PROS+ and issued a Study May Proceed letter, clearing the way for…
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancer Bria-PROS+ is BriaCell's next generation personalize...
BriaCell announces Odette Cancer Centre joins Bria-IMT trial
BriaCell (BCTX) announced that the Odette Cancer Centre at Sunnybrook Health Sciences Centre has joined BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in meta...
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...
BriaCell arranges scalable manufacturing with Fujifilm Biotechnologies
BriaCell (BCTX) announced a manufacturing arrangement with Fujifilm Biotechnologies California, a contract development and manufacturing organization specializing in cell therapies, to support the ong...
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™
PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™
PHILADELPHIA and VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...
BriaCell Partners With Uneedle To Support Scalable Microneedle Delivery Of Bria-IMT
(RTTNews) - BriaCell Therapeutics Corp. (BCTX), a clinical-stage biotechnology company developing novel immunotherapies for cancer, has entered into a Memorandum of Understanding with Uneedle, a Nethe...
BriaCell enters MoU with Uneedle for microneedle technology
BriaCell (BCTX) has entered into a memorandum of understanding, or MoU, with Uneedle to support the continued use and commercial readiness of Uneedle’s proprietary microneedle technology for intraderm...
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™
PHILADELPHIA and VANCOUVER, British Columbia, June 25, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...
BriaCell Therapeutics Quarterly report: Q3 2026
BriaCell Therapeutics has published its Q3 2026 quarterly earnings report on June 9, 2026.
BriaCell Therapeutics MD&A: Q3 2026
BriaCell Therapeutics filed a regulatory document on June 9, 2026 disclosing important business information.
BriaCell Therapeutics Report: Q3 2026
BriaCell Therapeutics published a report on June 9, 2026 containing material business information for investors and shareholders.
BriaCell Therapeutics Announces Closing of Offering
PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotec...